Osaki et al. “Potent antitumor effects and mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18),” Gene Ther. 6 (5): 808-815, May 1999.* |
Mountain, Andrew, “Gene therapy: the first decade”, Trends in Biotechnology, vol. 18, pp. 119-128 (Mar. 2000). |
Micallef, Mark J., et al., “Interleukin 18 Induces the Sequential Activation of Natural Killer Cells and Cytotoxic T Lymphocytes to Protect Syngeneic Mice from Transplantation with Meth A Sarcoma”, Cancer Research, vol. 57, pp. 4557-4563 (Oct. 15, 1997). |
Kyung-Sun Hwang, et al., “The Antitumor Effects of the Recombinant Adenoviruses Encoding IL-18 Mutants in Murine Tumor Model”, Proceedings of the American Association for Cancer Research, vol. 42, No. 2444, pp. 454-455, plus 20 pages from a slide presentation (Mar. 2001). |
Dinarello, Charles A., et al., “Overview of interleukin-18: more than an interferon-β inducing factor”, Journal of Leukocyte Biology, vol. 63, pp. 658-664 (Jun. 1998). |
Gennaro, Alfonso R. ed., Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, Chapters 83, 84, and 85, pp. xv, xvi, and 1519-1580 (1990). |